Trial Search Results
Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody
The purpose of this study is to assess the safety and tolerability of Hu5F9-G4 in participants with solid tumors.
Stanford is currently accepting patients for this trial.
Forty Seven, Inc.
- Drug: Hu5F9-G4
Patients with histologically or cytologically confirmed advanced solid malignancy or
Relapsed or refractory disease after at least 1 prior systemic treatment for the primary
malignancy and not a candidate for other curative treatment.
Adequate hematologic status
Adequate coagulation function
Adequate hepatic function
Adequate renal function
Known primary tumors of central nervous system disease
Known active brain metastases
Known cardiopulmonary disease
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study